Sign Out
Pregnancy: The effect on pregnancy and lactation has not been investigated in humans. Pramipexole should not be used during pregnancy unless clearly necessary, i.e. if the potential benefit justifies the potential risk to the fetus.
Breastfeeding: As Pramipexole treatment inhibits secretion of prolactin in humans, inhibition of lactation is expected. The excretion of pramipexole into breast milk has not been studied in women. In rats, the concentration of active substances-related radioactivity was higher in breast milk than in plasma.
In the absence of human data, Pramipexole should not be used during breastfeeding. However, if its use is unavoidable, breastfeeding should be discontinued.
Fertility: No studies on the effect on human fertility have been conducted.
